Best timing of EGFR re-challenge by monitoring the mutant allele of KRAS/NRAS in liquid biopsy

ABSTRACT: Primary outcome(s): The dynamics of the positive RAS mutations rate by circulating tumor DNA analysis using OncoBEAM RAS CRC KIT

DISEASE(S): Patients With Ras/braf V600e Wild-type Unresectable Advanced Or Recurrent Colorectal Cancer Who Have Been Treated With Anti-egfr Monoclonal Antibody

PROVIDER: 2651470 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR